Inovio Pharmaceuticals, Inc. is a biotechnology firm focused on researching, developing, and bringing to market DNA-based treatments designed to address and safeguard individuals from conditions linked to human papillomavirus (HPV), various cancers, and infectious diseases. Their innovative DNA medicines platform incorporates precisely engineered SynCon technology, which identifies and refines the genetic blueprint of the intended antigen, along with CELLECTRA smart device technology to facilitate the efficient administration of DNA plasmids. The company's developmental pipeline features several key programs: VGX-3100 for HPV-associated cervical high-grade dysplasia; INO-3107, currently in Phase 1/2 trials for HPV-related recurrent respiratory papillomatosis; INO-3112, a Phase 2 asset for HPV-related Oropharyngeal Squamous Cell Carcinoma; INO-5401, also in Phase 2, targeting glioblastoma multiforme; INO-4201, undergoing Phase 1b investigation for Ebola Virus Disease; INO-4800, which has advanced to Phase 3 for COVID-19; and INO-6160, in Phase 1 for human immunodeficiency virus. Inovio collaborates with an extensive network of partners and allies, including Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute. Established in 1983, the company's corporate headquarters are located in Plymouth Meeting, Pennsylvania.
